Filing Details

Accession Number:
0001179110-12-014180
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-09-17 22:12:01
Reporting Period:
2012-09-13
Filing Date:
2012-09-17
Accepted Time:
2012-09-17 21:12:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1158223 Affymax Inc AFFY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1419579 Anne-Marie Duliege C/O Affymax, Inc.
4001 Miranda Ave.
Palo Alto CA 94304
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-09-13 2,500 $4.36 35,329 No 4 M Direct
Common Stock Acquisiton 2012-09-13 16,666 $5.83 51,995 No 4 M Direct
Common Stock Acquisiton 2012-09-13 4,061 $7.99 56,056 No 4 M Direct
Common Stock Disposition 2012-09-13 23,227 $20.00 32,829 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2012-09-13 2,500 $0.00 2,500 $4.36
Common Stock Stock Option (Right to Buy) Disposition 2012-09-13 16,666 $0.00 16,666 $5.83
Common Stock Stock Option (Right to Buy) Disposition 2012-09-13 4,061 $0.00 4,061 $7.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-09 No 4 M Direct
23,334 2020-09-21 No 4 M Direct
44,689 2022-01-30 No 4 M Direct
Footnotes
  1. Fully vested..
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  3. The shares vest and become exercisable in a series of forty-eight successive equal monthly installments over the four (4) year period measured from September 22, 2010.
  4. The shares vest and become exercisable in a series of forty-eight (48) successive euqal monthly installments over the four (4) year period measured from January 1, 2012.